ALK G1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor
Abstract Inflammatory myofibroblastic tumors are rare mesenchymal neoplasms frequently harboring oncogenic chromosomal rearrangements, most commonly, involving the ALK (anaplastic lymphoma kinase) gene. Treatment of this molecularly defined subgroup with the anaplastic lymphoma kinase inhibitor criz...
Guardado en:
Autores principales: | Sebastian Y. F. Michels, Andreas H. Scheel, Thomas Wündisch, Johannes M. Heuckmann, Roopika Menon, Michael Puesken, Carsten Kobe, Helen Pasternack, Carina Heydt, Matthias Scheffler, Rieke Fischer, Anne M. Schultheis, Sabine Merkelbach-Bruse, Lukas Heukamp, Reinhard Büttner, Jürgen Wolf |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/33a80232e38044a3a05d9a9bbd74b52a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells
por: Joelle C. Boulos, et al.
Publicado: (2021) -
ALK and IGF-1R as independent targets in crizotinib resistant lung cancer
por: Christabel Wilson, et al.
Publicado: (2017) -
Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer
por: Caiyu Lin, et al.
Publicado: (2021) -
Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
por: Giroux Leprieur E, et al.
Publicado: (2016) -
Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
por: Deng L, et al.
Publicado: (2018)